申请人:Sankyo Company, Limited
公开号:US06362179B1
公开(公告)日:2002-03-26
Hydrochloride of fumarate of 1-{2-[(2R)-(3,4-dichlorophenyl)-4-(3,4,5-trimethyoxybenzoyl)morpholin-2-yl]ethyl}spiro[benzo(c)thiophene-1(3H),4′-piperidin]-(2S)-oxide. These compounds have good oral adsorption and exhibit markedly excellent antagonistic action against both NK1 receptors and NK2 receptors. These compounds are useful as an active ingredient in pharmaceutical compositions for administering to patients for treatment of tachykinin-medicated diseases.
富马酸盐羟氯喹啉-1-{2-[(2R)-(3,4-二氯苯基)-4-(3,4,5-三甲氧基苯甲酰)吗啡啉-2-基]乙基}螺[苯并(c)噻吩-1(3H),4′-哌啶]-(2S)-氧化物。这些化合物口服吸收良好,并对NK1受体和NK2受体表现出明显的拮抗作用。这些化合物可用作药物组合物中的活性成分,用于治疗Tachykinin介导的疾病。